Inventiva Unveils Positive Lanifibranor Data Ahead of Phase 3 Readout
Event summary
- Inventiva to present five abstracts at Paris MASH 2026 on September 10-11, showcasing Phase 1/2 clinical and preclinical data for lanifibranor.
- Phase 2 data demonstrates lanifibranor improves metabolic profile and cardiovascular risk factors in MASH patients with/without type 2 diabetes.
- Preclinical studies highlight lanifibranor's differentiated fluid and cardiac profile compared to other PPAR agonists.
- Phase 3 NATiV3 trial results for MASH with moderate/advanced fibrosis expected Q4 2026.
The big picture
Inventiva's data presentations come at a critical juncture as the biopharmaceutical industry increasingly focuses on metabolic disease treatments. The company's pan-PPAR approach represents a strategic shift from traditional single-target therapies, potentially offering a more comprehensive solution for MASH patients. With Phase 3 results imminent, the market will be watching closely to see if lanifibranor can deliver on its promise of improved metabolic and cardiovascular outcomes.
What we're watching
- Regulatory Pathway
- Whether the Breakthrough Therapy designation will accelerate FDA review process following Phase 3 results.
- Clinical Efficacy
- How the differentiated cardiovascular profile will position lanifibranor against competitors in MASH treatment.
- Market Potential
- The pace at which Inventiva can commercialize lanifibranor if approved, given its pan-PPAR differentiation.